Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2176 participants.
Also called NCT02957682
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,176 participants
- Sponsor
- Registry
-
NCT02957682 -
2016-003189-16
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Chile, Estonia, Japan, Mexico, Russia, South Africa, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02957682. Randomized; quadruple masking; primary purpose treatment. Start 2016-11-02 (actual); primary completion 2020-03-05 (actual). Results posted on 2021-05-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Praluent (Alirocumab)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct02957682- Content hash
ef7990a3330ca949e0f5f6123302beb6e0254f54e68096efb2c1d176c7f120cd